A University of Queensland-led effort reported a precision strategy against drug-resistant bacteria that activates immune-cell mitochondrial fission, leveraging innate mechanisms rather than conventional direct bacterial killing. The approach centers on mitochondrial fission in immune cells as a functional lever to improve bacterial control, aiming to sidestep growing resistance pressures. At the platform level, researchers at the University of Pennsylvania unveiled ApexGO, a generative AI method for peptide antibiotic optimization. Unlike systems that start from large screening libraries, ApexGO begins with a smaller set of imperfect candidates and iteratively improves them using a predictive algorithm; the report cites 85% bacterial-growth halting and 72% outperformance versus parent peptides in lab tests. Together, the stories point to an industry focus on both biological re-framing of antibiotic action and computational acceleration of candidate optimization—two routes to keep pace with resistance.